Rabe, Klaus F.
Klaus F. Rabe
VIAF ID: 140328141 (Personal)
Permalink: http://viaf.org/viaf/140328141
Preferred Forms
- 100 0 _ ‡a Klaus F. Rabe
- 100 1 _ ‡a Rabe, Klaus F.
- 100 1 _ ‡a Rabe, Klaus F.
- 100 1 _ ‡a Rabe, Klaus F.
- 100 1 _ ‡a Rabe, Klaus F.
4xx's: Alternate Name Forms (7)
5xx's: Related Names (1)
- 551 _ _ ‡a Kiel ‡4 ortw ‡4 https://d-nb.info/standards/elementset/gnd#placeOfActivity
Works
Title | Sources |
---|---|
COPD and comorbidity | |
Correction to: Key summary of German national treatment guidance for hospitalized COVID‑19 patients Key pharmacologic recommendations from a national German living guideline using an Evidence to Decision Framework (last updated 17.05.2021) | |
Human alveolar epithelial cells type II are capable of TGFβ-dependent epithelial-mesenchymal-transition and collagen-synthesis | |
Human isolated airways : an in vitro model for the investigation of airway smooth muscle (patho)physiology and its pharmacological modulation | |
Inhalative Glukokortikoide zur Therapie obstruktiver Ventilationsstörungen | |
multi-modal effect of the anti-fibrotic drug pirfenidone on NSCLC | |
Phosphodiesterase-4-Hemmer-Roflumilast Fortschritt bei der Therapie der COPD | |
Phosphodiesterase inhibitors, 1996: | |
Risk Assessment for Patients with Chronic Respiratory Conditions in the Context of the SARS-CoV-2 Pandemic Statement of the German Respiratory Society with the Support of the German Association of Chest Physicians |